CA2549652C - Cd40 antibody formulation and methods - Google Patents

Cd40 antibody formulation and methods Download PDF

Info

Publication number
CA2549652C
CA2549652C CA2549652A CA2549652A CA2549652C CA 2549652 C CA2549652 C CA 2549652C CA 2549652 A CA2549652 A CA 2549652A CA 2549652 A CA2549652 A CA 2549652A CA 2549652 C CA2549652 C CA 2549652C
Authority
CA
Canada
Prior art keywords
antibody
ser
val
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2549652A
Other languages
English (en)
French (fr)
Other versions
CA2549652A1 (en
Inventor
Vahe Bedian
John Daniel Cusmano
Ronald Paul Gladue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2549652(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to CA2704300A priority Critical patent/CA2704300A1/en
Publication of CA2549652A1 publication Critical patent/CA2549652A1/en
Application granted granted Critical
Publication of CA2549652C publication Critical patent/CA2549652C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2549652A 2003-12-22 2004-12-09 Cd40 antibody formulation and methods Expired - Lifetime CA2549652C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2704300A CA2704300A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22
US60/531,639 2003-12-22
PCT/IB2004/004103 WO2005063289A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2704300A Division CA2704300A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Publications (2)

Publication Number Publication Date
CA2549652A1 CA2549652A1 (en) 2005-07-14
CA2549652C true CA2549652C (en) 2013-11-12

Family

ID=34738672

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2549652A Expired - Lifetime CA2549652C (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods
CA2704300A Abandoned CA2704300A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2704300A Abandoned CA2704300A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Country Status (20)

Country Link
US (4) US20050136055A1 (https=)
EP (3) EP1706143A1 (https=)
JP (3) JP2007515469A (https=)
KR (2) KR20080023766A (https=)
CN (2) CN102552905A (https=)
AU (1) AU2004308749B2 (https=)
BR (1) BRPI0418029B8 (https=)
CA (2) CA2549652C (https=)
DK (1) DK2218461T3 (https=)
ES (1) ES2580002T3 (https=)
HU (1) HUE027717T2 (https=)
IL (2) IL175540A (https=)
NO (1) NO343797B1 (https=)
NZ (2) NZ583179A (https=)
PL (1) PL2218461T3 (https=)
RU (1) RU2355421C2 (https=)
SI (1) SI2218461T1 (https=)
TW (1) TWI359671B (https=)
WO (1) WO2005063289A1 (https=)
ZA (1) ZA200603804B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090304687A1 (en) * 2005-12-09 2009-12-10 Seattle Genetics , Inc. Methods of using cd40 binding agents
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2735421A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
PT3444271T (pt) 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
BR112017008959A2 (pt) 2014-10-29 2018-01-16 Seattle Genetics, Inc. método para tratamento de uma doença.
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CA3042867A1 (en) 2016-11-04 2018-05-11 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN111344304B (zh) 2017-06-01 2023-09-01 Pb免疫治疗公司 新型抗cd40抗体及其用途
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
EP3630827A1 (en) * 2017-06-02 2020-04-08 H. Hoffnabb-La Roche Ag Administration routes for immune agonists
AU2019255781A1 (en) 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
JP7626698B2 (ja) * 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
CN112996818B (zh) * 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
US20240254248A1 (en) * 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
CN113271964A (zh) 2019-01-11 2021-08-17 诺华股份有限公司 化脓性汗腺炎治疗中使用的抗cd40抗体
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
US20230227567A1 (en) * 2020-06-04 2023-07-20 Selvax Pty Ltd Agonist anti-cd40 antibodies
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
NZ273504A (en) * 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
EP1181054A1 (en) * 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1322383B9 (en) * 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7771951B2 (en) * 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
US20050136055A1 (en) 2005-06-23
US20090311254A1 (en) 2009-12-17
NZ547162A (en) 2010-03-26
SI2218461T1 (sl) 2016-08-31
DK2218461T3 (en) 2016-05-17
PL2218461T3 (pl) 2016-09-30
CA2704300A1 (en) 2005-07-14
JP2007515469A (ja) 2007-06-14
ES2580002T3 (es) 2016-08-18
CN1897971A (zh) 2007-01-17
BRPI0418029B1 (pt) 2018-12-26
US20120263732A1 (en) 2012-10-18
IL201409A0 (en) 2010-05-31
EP3081933A1 (en) 2016-10-19
HUE027717T2 (en) 2016-10-28
IL175540A (en) 2011-10-31
BRPI0418029A (pt) 2007-04-17
NO343797B1 (no) 2019-06-11
US20110104182A1 (en) 2011-05-05
CA2549652A1 (en) 2005-07-14
AU2004308749A1 (en) 2005-07-14
BRPI0418029B8 (pt) 2021-05-25
RU2355421C2 (ru) 2009-05-20
IL175540A0 (en) 2006-09-05
EP1706143A1 (en) 2006-10-04
CN102552905A (zh) 2012-07-11
JP2014205692A (ja) 2014-10-30
ZA200603804B (en) 2007-09-26
RU2006120950A (ru) 2008-01-27
NZ583179A (en) 2011-06-30
KR20080023766A (ko) 2008-03-14
JP2011184446A (ja) 2011-09-22
KR100847944B1 (ko) 2008-07-22
TWI359671B (en) 2012-03-11
AU2004308749B2 (en) 2010-10-28
WO2005063289A1 (en) 2005-07-14
NO20063373L (no) 2006-09-21
KR20070012626A (ko) 2007-01-26
EP2218461A1 (en) 2010-08-18
JP5634321B2 (ja) 2014-12-03
TW200521142A (en) 2005-07-01
EP2218461B1 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
CA2549652C (en) Cd40 antibody formulation and methods
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP2017515815A (ja) レナリドミド及びポリペプチド構築物の組合せ、及びその使用
US20240425579A1 (en) Compositions and methods that inhibit il-23 signaling
JP7644151B2 (ja) 抗ｐｄ－１抗体および融合タンパク質
KR20220042067A (ko) Gm-csf 길항제를 사용한 암의 치료
TW202216193A (zh) 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
US20230057939A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
WO2023001118A1 (zh) 抗ox40抗体在联合用药中的应用
KR20230129467A (ko) 항-푸코실-gm1 항체를 사용하는 조합 요법
MXPA06006153A (en) Cd40 antibody formulation and methods
HK1172823A (en) Cd40 antibody formulation and methods
TW201713346A (zh) 調控免疫反應之方法及抗體

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240722